Daniel Gorovets1, Diandra Ayala-Peacock2, David J Tybor3, Paul Rava4, Daniel Ebner5, Deus Cielo6, Georg Norén6, David E Wazer5, Michael Chan7, Jaroslaw T Hepel8. 1. Department of Radiation Oncology, Rhode Island Hospital, Brown University Warren Alpert Medical School, Providence, Rhode Island; Department of Radiation Oncology, Perlmutter Cancer Center, NYU School of Medicine, New York, New York. 2. Department of Radiation Oncology, Wake Forest School of Medicine, Winston-Salem, North Carolina; Department of Radiation Oncology, Vanderbilt University School of Medicine, Nashville, Tennessee. 3. Department of Public Health and Community Medicine, Tufts University School of Medicine, Boston, Massachusetts. 4. Department of Radiation Oncology, Rhode Island Hospital, Brown University Warren Alpert Medical School, Providence, Rhode Island; Department of Radiation Oncology, UMass Memorial Medical Center, University of Massachusetts School of Medicine, Worcester, Massachusetts. 5. Department of Radiation Oncology, Rhode Island Hospital, Brown University Warren Alpert Medical School, Providence, Rhode Island. 6. Department of Neurosurgery, Rhode Island Hospital, Brown University Warren Alpert Medical School, Providence, Rhode Island. 7. Department of Radiation Oncology, Wake Forest School of Medicine, Winston-Salem, North Carolina. 8. Department of Radiation Oncology, Rhode Island Hospital, Brown University Warren Alpert Medical School, Providence, Rhode Island. Electronic address: jhepel@lifespan.org.
Abstract
PURPOSE: Optimal patient selection for stereotactic radiosurgery (SRS) as the initial treatment for brain metastases is complicated and controversial. This study aimed to develop a nomogram that predicts survival without salvage whole brain radiation therapy (WBRT) after upfront SRS. METHODS AND MATERIALS: Multi-institutional data were analyzed from 895 patients with 2095 lesions treated with SRS without prior or planned WBRT. Cox proportional hazards regression model was used to identify independent pre-SRS predictors of WBRT-free survival, which were integrated to build a nomogram that was subjected to bootstrap validation. RESULTS: Median WBRT-free survival was 8 months (range, 0.1-139 months). Significant independent predictors for inferior WBRT-free survival were age (hazard ratio [HR] 1.1 for each 10-year increase), HER2(-) breast cancer (HR 1.6 relative to other histologic features), colorectal cancer (HR 1.4 relative to other histologic features), increasing number of brain metastases (HR 1.09, 1.32, 1.37, and 1.87 for 2, 3, 4, and 5+ lesions, respectively), presence of neurologic symptoms (HR 1.26), progressive systemic disease (HR 1.35), and increasing extracranial disease burden (HR 1.31 for oligometastatic and HR 1.56 for widespread). Additionally, HER2(+) breast cancer (HR 0.81) and melanoma (HR 1.11) trended toward significance. The independently weighted hazard ratios were used to create a nomogram to display estimated probabilities of 6-month and 12-month WBRT-free survival with a corrected Harrell's C concordance statistic of 0.62. CONCLUSIONS: Our nomogram can be used at initial evaluation to help select patients best suited for upfront SRS for brain metastases while reducing expense and morbidity in patients who derive minimal or no benefit.
PURPOSE: Optimal patient selection for stereotactic radiosurgery (SRS) as the initial treatment for brain metastases is complicated and controversial. This study aimed to develop a nomogram that predicts survival without salvage whole brain radiation therapy (WBRT) after upfront SRS. METHODS AND MATERIALS: Multi-institutional data were analyzed from 895 patients with 2095 lesions treated with SRS without prior or planned WBRT. Cox proportional hazards regression model was used to identify independent pre-SRS predictors of WBRT-free survival, which were integrated to build a nomogram that was subjected to bootstrap validation. RESULTS: Median WBRT-free survival was 8 months (range, 0.1-139 months). Significant independent predictors for inferior WBRT-free survival were age (hazard ratio [HR] 1.1 for each 10-year increase), HER2(-) breast cancer (HR 1.6 relative to other histologic features), colorectal cancer (HR 1.4 relative to other histologic features), increasing number of brain metastases (HR 1.09, 1.32, 1.37, and 1.87 for 2, 3, 4, and 5+ lesions, respectively), presence of neurologic symptoms (HR 1.26), progressive systemic disease (HR 1.35), and increasing extracranial disease burden (HR 1.31 for oligometastatic and HR 1.56 for widespread). Additionally, HER2(+) breast cancer (HR 0.81) and melanoma (HR 1.11) trended toward significance. The independently weighted hazard ratios were used to create a nomogram to display estimated probabilities of 6-month and 12-month WBRT-free survival with a corrected Harrell's C concordance statistic of 0.62. CONCLUSIONS: Our nomogram can be used at initial evaluation to help select patients best suited for upfront SRS for brain metastases while reducing expense and morbidity in patients who derive minimal or no benefit.
Authors: Rachel F Shenker; Emory R McTyre; Glen B Taksler; Ralph B D'Agostino; Christina K Cramer; Jimmy Ruiz; Natalie K Alphonse-Sullivan; Michael Farris; Kounosuke Watabe; Fei Xing; Adrian W Laxton; Stephen B Tatter; Michael D Chan Journal: Clin Neurol Neurosurg Date: 2018-11-13 Impact factor: 1.876
Authors: Brahma D Natarajan; Christel N Rushing; Michael A Cummings; Jessica Ms Jutzy; Kingshuk R Choudhury; Michael J Moravan; Peter E Fecci; Justus Adamson; Steven J Chmura; Michael T Milano; John P Kirkpatrick; Joseph K Salama Journal: J Radiosurg SBRT Date: 2019
Authors: David M Routman; Shelly X Bian; Kevin Diao; Jonathan L Liu; Cheng Yu; Jason Ye; Gabriel Zada; Eric L Chang Journal: Cancer Med Date: 2018-02-14 Impact factor: 4.452
Authors: Ali Rae; Daniel Gorovets; Paul Rava; Daniel Ebner; Deus Cielo; Timothy J Kinsella; Thomas A DiPetrillo; Jaroslaw T Hepel Journal: Adv Radiat Oncol Date: 2016-08-24
Authors: Yuanxuan Xia; Leila A Mashouf; Brock R Baker; Russell Maxwell; Chetan Bettegowda; Kristin J Redmond; Lawrence R Kleinberg; Michael Lim Journal: Cureus Date: 2018-07-30
Authors: Angelika Bilger; Eva Bretzinger; Jamina Fennell; Carsten Nieder; Hannah Lorenz; Oliver Oehlke; Anca-Ligia Grosu; Hanno M Specht; Stephanie E Combs Journal: Cancer Med Date: 2018-05-09 Impact factor: 4.452